Xencor (NASDAQ:XNCR) Stock Rating Upgraded by Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Xencor (NASDAQ:XNCR) from a strong sell rating to a hold rating in a research note published on Saturday, Zacks.com reports.

According to Zacks, “Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California. “

A number of other equities research analysts have also weighed in on XNCR. Guggenheim lowered Anadarko Petroleum from a buy rating to a hold rating and set a $69.00 target price for the company. in a research report on Friday, April 12th. BidaskClub raised Zynerba Pharmaceuticals from a hold rating to a buy rating in a research report on Thursday, June 20th. Berenberg Bank decreased their target price on Lucara Diamond from C$1.60 to C$1.50 in a research report on Wednesday, March 27th. Cantor Fitzgerald reaffirmed a buy rating and set a $40.00 target price on shares of Xencor in a research report on Sunday, May 12th. Finally, Piper Jaffray Companies set a $92.00 target price on Wintrust Financial and gave the company a buy rating in a research report on Monday, July 8th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of Buy and an average target price of $43.44.

XNCR opened at $44.41 on Friday. The company has a current ratio of 6.66, a quick ratio of 6.66 and a debt-to-equity ratio of 0.02. The firm’s fifty day simple moving average is $38.78. The stock has a market cap of $2.50 billion, a PE ratio of -33.90 and a beta of 1.45. Xencor has a 52-week low of $27.75 and a 52-week high of $48.38.

Xencor (NASDAQ:XNCR) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported $1.38 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.43 by $0.95. The firm had revenue of $111.94 million for the quarter, compared to the consensus estimate of $60.05 million. Sell-side analysts anticipate that Xencor will post -0.08 EPS for the current fiscal year.

In related news, major shareholder John S. Stafford III purchased 14,611 shares of Xencor stock in a transaction dated Thursday, May 2nd. The stock was purchased at an average cost of $29.87 per share, with a total value of $436,430.57. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder John S. Stafford III purchased 12,641 shares of Xencor stock in a transaction dated Thursday, June 6th. The stock was bought at an average cost of $29.87 per share, with a total value of $377,586.67. The disclosure for this purchase can be found here. Insiders own 4.33% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Oregon Public Employees Retirement Fund purchased a new position in shares of Xencor during the second quarter worth $409,000. Louisiana State Employees Retirement System purchased a new position in shares of Xencor during the second quarter worth $794,000. First Trust Advisors LP boosted its position in shares of Xencor by 185.4% during the first quarter. First Trust Advisors LP now owns 69,783 shares of the biopharmaceutical company’s stock worth $2,167,000 after buying an additional 45,331 shares during the period. Marshall Wace LLP purchased a new position in shares of Xencor during the first quarter worth $797,000. Finally, DekaBank Deutsche Girozentrale boosted its position in shares of Xencor by 22.1% during the first quarter. DekaBank Deutsche Girozentrale now owns 18,200 shares of the biopharmaceutical company’s stock worth $765,000 after buying an additional 3,300 shares during the period. 83.52% of the stock is owned by hedge funds and other institutional investors.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

Featured Article: Debt-To-Equity Ratio

Get a free copy of the Zacks research report on Xencor (XNCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Boston Private Financial  Upgraded at ValuEngine
Boston Private Financial Upgraded at ValuEngine
Axsome Therapeutics  Upgraded at Zacks Investment Research
Axsome Therapeutics Upgraded at Zacks Investment Research
Sunworks  Cut to “Sell” at Zacks Investment Research
Sunworks Cut to “Sell” at Zacks Investment Research
TPI Composites  Lifted to Strong-Buy at Raymond James
TPI Composites Lifted to Strong-Buy at Raymond James
Verb Technology  Earns Buy Rating from Analysts at Alliance Global Partners
Verb Technology Earns Buy Rating from Analysts at Alliance Global Partners
Insider Selling: KB Home  EVP Sells $280,200.00 in Stock
Insider Selling: KB Home EVP Sells $280,200.00 in Stock


 
© 2006-2019 Zolmax.